Cusimano Lucas D, Maestas Nicole
Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
JAMA Health Forum. 2024 Dec 6;5(12):e244544. doi: 10.1001/jamahealthforum.2024.4544.
Concerns around excessive opioid prescribing have been used to argue against the expansion of the scope of practice of nurse practitioners (NPs), but the association of NP practice independence with high-risk opioid prescribing is not well understood.
To assess whether the rates of high-risk opioid prescribing changed in association with NP independence legislation.
DESIGN, SETTING, AND PARTICIPANTS: This difference-in-differences analysis compared rates of high-risk opioid prescribing in 6 states over 2 years following the adoption of NP independence compared with 10 neighboring nonadopting states from January 2012 to December 2021. Prescription insurance claims for 2 874 213 continuously enrolled individuals (members) aged 18 to 64 years from Blue Cross Blue Shield Axis were analyzed. Data analysis was carried out from 2021 to 2024.
Timing of the legislative effective date of NP independence in a state.
The primary outcome was the rate of opioid prescriptions that overlapped with a prescription for a central nervous system (CNS) depressant. Secondary outcomes included the number of days of opioid-CNS depressant overlap, as well as the dosage and days supplied of opioids among all members and among opioid-naive members.
Six states that adopted NP independence legislation and 10 nonadopting neighboring states were similar in terms of demographic characteristics and had comparable pretrends in prescribing. The estimated change in the rate of opioid prescriptions that overlapped with a CNS depressant was -0.03 per 100 members per month (95% CI, -0.11 to 0.05). Changes in the number of days of opioid-CNS depressant overlap and in the dosage and days supplied of opioids among all members and among opioid-naive members were also small and statistically insignificant.
The results of this difference-in-differences analysis suggest that there was no relative increase in rates of high-risk opioid prescribing during the 2 years following the adoption of independence for NPs.
围绕阿片类药物过度处方的担忧被用来反对扩大执业护士(NP)的执业范围,但NP执业独立性与高风险阿片类药物处方之间的关联尚未得到充分理解。
评估高风险阿片类药物处方率是否随NP独立立法而变化。
设计、设置和参与者:这种差异分析比较了2012年1月至2021年12月期间,6个采用NP独立立法的州在立法通过后的2年里与10个相邻未采用该立法的州的高风险阿片类药物处方率。分析了来自蓝十字蓝盾轴心的2874213名年龄在18至64岁之间持续参保的个人(成员)的处方保险索赔。数据分析于2021年至2024年进行。
一个州NP独立立法的生效日期。
主要结局是与中枢神经系统(CNS)抑制剂处方重叠的阿片类药物处方率。次要结局包括阿片类药物与CNS抑制剂重叠的天数,以及所有成员和未使用过阿片类药物成员中阿片类药物的剂量和供应天数。
6个采用NP独立立法的州和10个未采用该立法的相邻州在人口特征方面相似,且处方的前期趋势相当。与CNS抑制剂重叠的阿片类药物处方率的估计变化为每月每100名成员-0.03(95%CI,-0.11至0.05)。阿片类药物与CNS抑制剂重叠天数以及所有成员和未使用过阿片类药物成员中阿片类药物剂量和供应天数的变化也很小且无统计学意义。
这种差异分析的结果表明,在NP获得独立后的2年里,高风险阿片类药物处方率没有相对增加。